carbachol has been researched along with vu0364572 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bridges, TM; Cho, HP; Conn, PJ; Daniels, JS; Digby, GJ; Lebois, EP; Lindsley, CW; Melancon, BJ; Miller, NR; Morrison, R; Sheffler, DJ; Tarr, JC; Wood, MR; Xiang, Z | 1 |
| Bridges, TM; Chauder, BA; Cho, HP; Conn, PJ; Daniels, JS; Gogliotti, RD; Lebois, EP; Lindsley, CW; Melancon, BJ; Morrison, RD; Niswender, CM; Saleh, SA; Sheffler, DJ; Tarr, JC; Utley, TJ; Wood, MR | 1 |
2 other study(ies) available for carbachol and vu0364572
| Article | Year |
|---|---|
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Central Nervous System; Humans; Muscarinic Agonists; Rats; Receptor, Muscarinic M1; Structure-Activity Relationship | 2011 |
Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor.
Topics: Humans; Molecular Probes; Receptors, Muscarinic | 2012 |